A new segment is about to split off the pharmaceutical division of the U.S. company Abbott this year. The company, to be named AbbVie, offers patented drugs and biologicals, and is directed by Richard Gonzales, previously vice chairman of Global Pharmaceuticals. The previous CEO Miles White will continue to lead Abbott.
The renaming was part of the splitting of the group into two publicly traded companies. Abbott continues to operate the remaining divisions: medical technology, diagnostics, medical nutrition and branded generics as well as the flu drug Influvac.
[ilink url=“http://www.apotheke-adhoc.de/nachrichten/markt/nachricht-detail-markt/abbotts-pharmasparte-wird-zu-abbvie/?tx_ttnews%5BsViewPointer%5D=1&cHash=91f6d7b3bcdee01a9d8784af95e3dbde“] Link zur Quelle (Apotheke Adhoc)[/ilink]